Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 May 06, 2026
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference May 04, 2026
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million Mar 30, 2026
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Mar 25, 2026
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 Mar 18, 2026
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million Feb 23, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease Feb 23, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Jan 13, 2026
